Ibrutinib inhibited the proliferation of GCB-DLBCL cell lines in a dose- and time-dependent manner. (A) SU-DHL-16 and OCI-LY7 cells (1 × 105/ml) were treated with the increasing concentrations (0.02 to 25 μM) of ibrutinib or DMSO for 24 hours. (B) SU-DHL-16 and OCI-LY7 cells (1 × 105/ml) were treated with10 μM of ibrutinib or DMSO for 6 to 48 hours. The viability of cells was determined using the Cell Titer-Glo luminescent cell viability assay as described in Materials and Methods. Results were expressed as the mean ± SD from triplicate cultures.